In patients with bronchial asthma, which biologic—mepolizumab or omalizumab—is more appropriate?

Biologic Selection for Bronchial Asthma: Mepolizumab vs Omalizumab

The choice between mepolizumab and omalizumab depends on your patient's asthma phenotype: use omalizumab for allergy-driven asthma and mepolizumab for eosinophilic asthma. 1

Phenotype-Based Selection Algorithm

Choose Omalizumab When:

• Allergy-driven asthma with documented perennial allergen sensitization and elevated IgE (30-1500 IU/mL) 1
• Female patients planning pregnancy (safest biologic option in this population) 1
• Patient has comorbid chronic spontaneous urticaria 2
• Younger patients (FDA-approved for ages 6 and up in asthma) 3

Choose Mepolizumab When:

• Eosinophilic asthma with blood eosinophils ≥150 cells/µL (or ≥300 cells/µL in prior year) 1
• Highly eosinophilic asthma with comorbid chronic rhinosinusitis with nasal polyps 1
• Patient requires greater exacerbation reduction - mepolizumab shows superior reduction in clinically significant exacerbations (IRR 0.37,95% CI 0.19-0.69) 4
• Patient needs reduction in systemic corticosteroid injections - omalizumab was superior in reducing corticosteroid injection use 5

Evidence-Based Performance Comparison

The most recent head-to-head real-world study (2026) demonstrates mepolizumab significantly reduces asthma exacerbations more than omalizumab in patients eligible for both therapies 4. This effect was particularly pronounced in patients with baseline eosinophils <300 cells/µL (IRR 0.38,95% CI 0.14-0.88) 4.

However, the clinical picture is nuanced:

• Asthma control: Both achieve similar improvements in Asthma Control Test scores, though omalizumab-treated patients report better quality of life (70.0% vs 46.9% excellent) 6
• Remission rates: Mepolizumab achieves 29.3% clinical remission vs 22.8% with omalizumab at 12 months 7
• Eosinophil reduction: Mepolizumab produces dramatically greater eosinophil reduction (87.8% vs 46.3%) 8
• Lung function: Mepolizumab shows trend toward greater FEV1 improvement (380 mL vs 215 mL), though not statistically significant 8

Critical Clinical Considerations

When Both Phenotypes Overlap (Atopic + Eosinophilic):

Approximately one-third of severe asthma patients qualify for both biologics 8. In this "overlap" population:

• Clinical efficacy is comparable between both agents 8
• Prioritize mepolizumab if exacerbation reduction is the primary goal 4
• Consider omalizumab if pregnancy is planned or quality of life is the priority 1, 6

Biomarker Thresholds Matter:

• High eosinophil counts (≥500 cells/µL) do not predict superior response to either biologic 8
• The presence of eosinophilia itself, rather than the absolute count, guides mepolizumab selection 1

Common Pitfalls to Avoid:

1. Don't assume higher eosinophils automatically mean better mepolizumab response - clinical efficacy is similar across eosinophil ranges 8
2. Don't overlook comorbidities - chronic spontaneous urticaria favors omalizumab; nasal polyps with high eosinophils favor mepolizumab 1
3. Don't forget pregnancy planning - omalizumab is the preferred choice for women of childbearing potential 1

Monitoring Response and Switching

If initial response is suboptimal after 16 weeks, switching between biologics is a valid strategy 9. Monitor:

• Inflammatory eosinophil (iEos) proportions - higher levels correlate with lower FEV1 and increased exacerbations 10
• Systemic steroid requirements
• Exacerbation frequency

The bottom line: Match the biologic to the dominant inflammatory pathway - IgE-mediated (omalizumab) or eosinophilic (mepolizumab) - while factoring in comorbidities and patient-specific priorities like pregnancy planning or exacerbation reduction.